Human IL-8 ELISA Kit
Product Specifications
- Catalogue N°
- 950.050.048 - 1 x 48 Discovery (pre-coated)
950.050.096 - 1 x 96 (pre-coated)
950.050.192 - 2 x 96 (pre-coated) - Assay Range
- 31.25 pg/ml - 1000 pg/ml
- Sensitivity
- 12.3 pg/ml
- Target species
- Human
- Specificity
- Recognizes both natural and recombinant human IL-8
- Incubation
- 2h15
- Sample Type
- Serum, Plasma, Cell culture supernatant
- Sample Size
- 100 µl
- Cross Reaction
- No cross reactivity with other human cytokines
- Kit Content
- Diaclone ELISA Kits include pre-coated strip plates, biotinylated secondary antibody, standards, controls (where applicable), buffers, streptavidin-HRP, TMB, stop reagents and a detailed procedure.
- Synonym
- CXCL8
References
- Hurtado, J.A. et al.,Breastfeed Med. 2017 May 1; 12(4): 202–209.
- Akbari, F. et al., Iran J Neurol.,2016; 15(2): 75-9. - Pubmed link
- Audibert, C. et al., Infect Immun., 2001; 69(3): 1625-9. - Pubmed link
- Backhed, F. et al., J. Biol. Chem., 2002; 277(20): 18198 - 19205 - Pubmed link
- Backhed, F. et al., Infect Immun., 2003; 71(6): 3357-60. - Pubmed link
- Bellanger, A.-P. et al.,Clin. Vaccine Immunol., 2013 ; 20(8): 1133-1142. - Pubmed link
- Bonnans, C. et al., Am J Pathol.,2006;168(4):1064-72. - Pubmed link
- Bote, M. E. et al.,PLoS One,2013;8(9):e74524 - Pubmed link
- Chabbert-de Ponnat, I. et al., Int Immunol.,2005; 17(4): 439-47. - Pubmed link
- Chavushyan, A. et al., Schizophr Res Treatment,2013: 125264 - Pubmed link
- Coconnier, M. H. et al., Appl Environ Microbiol.,2000; 66(3): 1152-7. - Pubmed link
- Eilertsen, G. O. et al.,Lupus,2011;20(6):607-613. - Pubmed link
- Eleftheriadis, T. et al.,Hippokratia,2011;15(3): 238-43 - Pubmed link
- Ellmerich S. et al., Carcinogenesis, 2000; 21(4): 753 -756 - Pubmed link
- Fan, H. et al., Mol Immunol.,2007; 44(12): 3092-9 - Pubmed link
- Gehrke, T. et al., Oncol Lett.,2016; 12(5): 3549-3554 - Pubmed link
- Giamarellos-Bourboulis, E. J. et al., Crit Care,2006; 10(3): R76 - Pubmed link
- Gironella J. et al., Gut, 2005; 54(9): 1244 - 1253 - Pubmed link
- Gombocz, K. et al., Crit Care,2007; 11(4): R87 - Pubmed link
- Guerrero, A. et al., Aging Cell,2015; 14(2): 274-83 - Pubmed link
- Hot, A. et al., Ann Rheum Dis, 2012; 71: 768 - 776. - Pubmed link
- Jaswal, S. et al.,Int J Appl Basic Med Res. 2018 Jan-Mar;8(1):14-18. - Pubmed link
- Krishna, S. et al., PLoS One,2011; 6(12): e28476 - Pubmed link
- Krzysiek, R. et al., J Immunol.,1999;162(8): 4455-63 - Pubmed link
- Kumpf, O. et al. ,Crit Care,2010; 14(3): R103. - Pubmed link
- Lee, H. W. et al.,Ann Dermatol.,2013;25(2):173-80 - Pubmed link
- Lekkou A. et al., Clin. Diagn.Lab. Immunol., 2004; 11(1):161 - 167 - Pubmed link
- Levy, B. D. et al., Prostaglandins Leukot Essent Fatty Acids,2011; 84(1-2): 43-50. - Pubmed link
- Maruyama, H. et al.,Lipids Health Dis.,2014; 13: 78 - Pubmed link
- Mazurkiewicz, P. et al.,Mol Microbiol.,2008; 67(6): 1371-83. - Pubmed link
- Rajappa, M. et al., Angiology,2009; 60(4): 419-426. - Pubmed link
- Rana, S. V. et al., J Crohns Colitis,2014;8(8):859-865 - Pubmed link
- Routsi, C. et al.,Clin Exp Immunol.,2005;142(1): 62-7. - Pubmed link
- Roy, S. et al.,Immunology,2004; 112(3): 471-80. - Pubmed link
- Rybka, J. et al.,Clin Exp Med.,2015; 16(4): 493-502. - Pubmed link
- Saraiva M. et al., JEM 2002; 196(6): 829-839 - Pubmed link
- Sell, H. et al., Am J Physiol Endocrinol Metab., 2008;294:E1070-E1077 - Pubmed link
- Sjolinder,H et al., Infect Immun., 2008; 76(9)3959-66 - Pubmed link
- Tenca C. et al., J. Immunol., 2005; 174(11): 6757 - 6763 - Pubmed link
- Toutirais, O. et al., Clin Exp Immunol.,2007; 149(2): 372-7 - Pubmed link
- Tsaganos, T. et al.,BMC Infect Dis.,2006; 6: 142. - Pubmed link
- Tutar, E. et al., World J Gastroenterol.,2008;14(20): 3218-23. - Pubmed link
- van de Sande, W.W.J. et al., J. Immunol.,2007; 179(5): 3065-3074. - Pubmed link
- Vassallo, R. et al.,Mol Immunol.,2008; 45(12): 3321-9. - Pubmed link
- Yadav, U. C. et al.,PLoS One,2009; 4(8): e6535 - Pubmed link
- Yadav, U. C. S. et al., J. Immunol.,2009; 183(7): 4723-4732. - Pubmed link
- Zhang, J. et al.,Tanaffos. 2017 Jun;16(4):260-269. - Pubmed link
- Zrioual, S. et al., J. Immunol.,2008; 180(1): 655-663. - Pubmed link
- Baos, S. et al.,Front Immunol. 2018 Jun 21;9:1416. - Pubmed link
- Baos, S. et al.,Front Immunol. 2019 May 9;10:1051. - Pubmed link
- Hijazi,Y. et al.,Curr Clin Pharmacol. 2018;13(1):55-64. - Pubmed link
- Kebenko, M. et al., Oncoimmunology. 2018 Apr 18;7(8):e1450710 - Pubmed link
- Molteni, M. et al.,Toxins (Basel). 2018 Jul 16;10(7). pii: E290 - Pubmed link
- Rodríguez-Luna, A. et al., Mar Drugs. 2018 Oct 10;16(10). pii: E378. - Pubmed link
- Antonucci, L. et al., J Immunol Res. 2020; 2020: 4570219. - Pubmed link
- Gutiérrez, M. et al., Mar Drugs. 2020 Feb; 18(2): 84. - Pubmed link
- Tuettenberg, A. et al., Exp Dermatol. 2007 Mar; 16(3): 171–178. - Pubmed link
- Parra-Izquierdo, I. et al., Int J Mol Sci. 2021 Oct; 22(19): 10605. - Pubmed link
- Ruggeri, M. et al., Pharmaceutics. 2021 Sep; 13(9): 1450. - Pubmed link
- Silvan, J.M. et al., Antioxidants (Basel) 2021 Dec; 10(12): 2030. - Pubmed link
- Silvan, J.M. et al., Antioxidants (Basel) 2021 Jun; 10(6): 943. - Pubmed link
- Angelova, G. et al., J Fungi (Basel) 2022 Jul; 8(7): 738. - Pubmed link
- Villalva, M. et al., Foods. 2022 Jul; 11(13): 1832. - Pubmed link
- Ogłodek, E., Brain Sci. 2022 Mar 14;12(3):387. - Pubmed link
- Flori, E. et al., iScience. 2022 Mar 18; 25(3): 103871. - Pubmed link
BACKGROUND
Interleukin 8 (IL-8) or CXCL8, Monocyte-Derived Neutrophil Chemotactic Factor (MDNCF), Neutrophil Activating Factor (NAF) and NAD-P1 is a chemokine secreted by monocytes, macrophages and endothelial cells. IL-8 chemoattracts and activates neutrophils.
The predominant form of IL-8 is a 8.4kDa protein containing 72 amino acid residues, which includes five additional N-Terminal amino-acids. IL-8 contains the four conserved cysteine residues present in CXC chemokines and also contains the “ELR” motif common to CXC chemokines that binds to CXCR1 and CXCR2.
Data indicate that IL-8 may participate in the pathogenesis of rheumatoid arthritis via the induction of neutrophil-mediated cartilage damage , and psoriasis. A causative involvement of IL-8 is found within a broad range of clinico-pathological conditions : adult respiratory distress syndrome, asthma, bacterial infections, bladder cancer, graft rejection and influenza infection, due to the now known biological properties of IL-8. This cytokine especially in combinations with other neutrophil activating agents, may prove helpful in the treatment of patients suffering from granulocytopenia, severe infections against which antibiotics are not effective, and immunodeficiency caused by HIV.
Version 25 - 09.22
For research use only
For any order, the purchaser acknowledges having read and accepted the terms and conditions described on the Diaclone website.